Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
6,772 total articles
ICU Medical, Inc. announced its first quarter 2026 financial results, showing GAAP revenue decline of 12% year-over-year primarily due to the strategic divestiture of the IV Solutions business. However, non-GAAP organic revenue increased by 1%, and profitability improved significantly with a GAAP net income of $30.1 million compared to a net loss i…
Profound Medical Corp. reported a strong first quarter for 2026, showcasing 104% revenue growth year-over-year, improved operating performance, and reduced net loss. Key achievements include expansion of installed TULSA-PRO systems, positive clinical trial results affirming safety superiority, and Humana becoming the first major US insurer to cover…
Organogenesis Holdings Inc. reported a challenging first quarter of 2026 with net revenue declining 58% year-over-year to $36.3 million, driven by a 63% decrease in Advanced Wound Care sales. The company posted a net loss of $53.2 million, significantly larger than the $18.8 million loss a year earlier. Operating expenses remained high at $106.1 mi…
Fidus Investment Corporation announced its Q1 2026 financial results highlighted by a 35.2% increase in net investment income to $24.6 million ($0.65 per share), a 30.2% rise in total investment income, and increased fee and interest income. The company declared a total dividend of $0.62 per share for Q2 2026, including a supplemental dividend of $…
ImmuCell Corporation, a Nasdaq-listed animal health biologics company specializing in calf health products, announced it will report its unaudited financial results for the quarter ended March 31, 2026, on May 14 after market close. The company plans a conference call on May 15 to discuss the results and expects no changes to previously announced p…
Myriad Genetics announced that its management will participate in the BofA Securities 2026 Health Care Conference and Goldman Sachs 47th Annual Global Healthcare Conference. These events provide platforms for investor engagement and sharing strategic insights about the company's molecular diagnostic testing and precision medicine initiatives.
NextCure announced a business update and financial results for Q1 2026, highlighting the FDA's Fast Track designation for its SIM0505 antibody-drug conjugate targeting platinum-resistant ovarian cancer. The company plans to present Phase 1 data at ASCO 2026 and expand clinical trial sites in North America and Europe. Financially, NextCure reported …
GSI Technology, Inc. announced its financial results for the fourth quarter and fiscal year ended March 31, 2026, highlighting a 22% revenue increase driven by higher SRAM sales and expanded gross margins. The company completed software milestones supporting the upcoming demonstration of its Gemini-II powered drone and secured $2 million in new U.S…
Sprout Social, Inc. announced its Q1 2026 financial results, showing 11% year-over-year revenue growth to $121.5 million and a 21% increase in subscription revenue contribution from customers with ARR $30K or more. The company reported $24.7 million non-GAAP free cash flow and improved profitability. They also initiated their first-ever $50 million…
Jade Biosciences announced their first quarter 2026 financial results and updated on clinical pipeline milestones, including upcoming Phase 1 and Phase 2 trials for their lead program JADE101 targeting IgA nephropathy, and initiation of trials for JADE201 and JADE301. The company holds $311 million in cash, enough to fund operations into mid-2028, …
Texas Roadhouse, Inc. announced its Q1 2026 financial results, highlighting a 12.8% increase in total revenue and an 8.6% increase in net income versus the prior year. Comparable restaurant sales grew by 7.1%. The company opened six new restaurants during the quarter, including franchise locations, and invested heavily in capital expenditures and a…
SoundHound AI announced a strong first quarter with revenue rising 52% year-over-year to $44.2 million, driven by demand in automotive and IoT AI verticals. The company launched the OASYS self-learning agentic AI platform and plans to acquire LivePerson, combining voice AI with digital messaging services for a robust enterprise presence. SoundHound…
Outset Medical released its Q1 2026 financial results, showing a 6% revenue decline but a significant gross margin expansion to 43.4%. Despite lower product revenue, recurring service revenue remained stable. The company reduced net loss compared to the prior year and maintained a strong cash position. Outset reiterated 2026 revenue guidance of $12…
Full House Resorts reported a strong first quarter for 2026 with consolidated revenues of $74.4 million and a 14.7% increase in Adjusted EBITDA to $13.2 million. The growth was primarily driven by American Place Casino's 7.1% revenue increase and operational improvements in Colorado properties. The company is advancing construction plans for a perm…
WillScot Holdings Corporation, a provider of innovative temporary space solutions, announced a quarterly cash dividend of $0.07 per share payable on June 17, 2026, to shareholders of record as of June 3, 2026. The company serves industries including construction, manufacturing, healthcare, government, energy, and education with a comprehensive prod…
Catalyst Pharmaceuticals, a U.S.-based biopharmaceutical company focused on rare diseases, has canceled its first quarter 2026 earnings conference call scheduled for May 12, following the announcement of its pending acquisition by Angelini Pharma S.p.A. The company will still release its Q1 2026 financial results on May 11 as planned.
Scorpio Tankers Inc. announced a proposed private offering to reopen its 1.75% convertible senior notes due 2031 by issuing an additional $150 million, with an option to increase by $22.5 million. Concurrently, the company plans to use part of the proceeds to repurchase its common stock, particularly shares sold short during the offering. The notes…
Progyny, a leader in women's health and family building benefits, announced a record revenue of $328.5 million for Q1 2026, marking a 1.4% growth year-over-year and a 12.2% increase excluding the non-renewing large client. The company highlights robust demand driven by societal shifts towards later family building and increased births among women o…
Turtle Beach Corporation reported Q1 2026 results including $42.2 million net revenue, $29.4 million cash flow from operations, and a net loss of $15.2 million. The company reaffirmed 2026 full year guidance with expected net revenue of $335–355 million and adjusted EBITDA of $44–48 million. Turtle Beach refinanced its credit facilities to improve …
Research Frontiers Inc. announced its first-quarter 2026 financial results, noting revenue was impacted by the timing of license agreement recognition and absence of prior year upfront revenue. The company advanced multiple strategic initiatives across automotive, aircraft, and architectural sectors using its SPD-Smart light-control technology. Whi…
Corvus Pharmaceuticals reported positive Phase 1 clinical data for its lead drug candidate, soquelitinib, in atopic dermatitis and initiated Phase 2 trials including additional indications like hidradenitis suppurativa and asthma. The company also continues enrolling in a Phase 3 trial for T cell lymphoma and collaborates with NIAID on a rare disea…
Gevo, Inc. announced solid financial and operational results for Q1 2026, exceeding expectations despite seasonality in ethanol margins. The company progressed on its debottlenecking and expansion projects at its North Dakota facility to increase low-carbon ethanol output by over 10% next year and aims to double capacity by 2028. Gevo also launched…
Denali Therapeutics announced FDA accelerated approval and U.S. commercial launch of AVLAYAH for Hunter syndrome, the first medicine leveraging the transferrin receptor to cross the blood-brain barrier. The company reported progress across its pipeline targeting Alzheimer's, frontotemporal dementia, Sanfilippo syndrome, Pompe disease, and Parkinson…
Annexon, Inc. reported its first quarter 2026 financial results and detailed significant progress and upcoming milestones across its neuroinflammatory disease therapy portfolio. Key upcoming catalysts include topline Phase 3 data for vonaprument targeting Geographic Atrophy (GA) expected in Q4 2026, regulatory review of tanruprubart for Guillain-Ba…
SIGA Technologies announced its financial results for Q1 2026, reporting net losses but highlighted planned deliveries of $13 million oral TPOXX to an international customer and $26 million IV TPOXX to the U.S. Government Strategic National Stockpile by Q3 2026. The company also secured an exclusive license agreement for oral TPOXX commercializatio…
